BML Capital Management, LLC
BML Capital Management, LLC reported 15 US-listed holdings worth $175.1 million in its 13F for the quarter ended 30 June 2026, filed 7 August 2026. Its largest: Aclaris Therapeutics Inc. (36.2%), Atea Pharmaceuticals Inc. (18.5%) and Engene Therapeut (6.6%). Against the quarter before, it opened 1 position, added to 5, trimmed 3 and sold out of 1.
The 14 largest of its 15 positions, each sized by its share of the reported holdings, coloured by the change in shares against Q1 2026.
What the fund reported holding at each quarter's end; hover a bar for the number of positions
What its reported holdings returned
Held through each quarter, the holdings it reported returned +85.9% over the 3 quarters to 30 June 2026, against +12.1% for the S&P 500.
Not the fund's own return: each 13F's holdings are kept unchanged until the next one, so trades inside a quarter, dividends, cash and fees are left out. A rough guide to how its picks have done over time.
What it did on the quarter
Its positions against its 13F for the quarter to 31 March 2026; a change under 0.1% of a position counts as held
Opened 1
- Engene Therapeut ENGN$11.5 million
Added to 5
- Kraft Heinz Co. KHC+340,000 shares · +272%
- Outset Med Inc. OM+617,500 shares · +32%
- Carmax Inc. KMX+17,500 shares · +11%
- Connect Biopharma Hldgs Ltd CNTB+164,400 shares · +40%
- PMV Pharmaceuticals Inc. PMVP+10,000 shares · +0%
Trimmed 3
- Aclaris Therapeutics Inc. ACRS-2.3 million shares · -16%
- Oramed Pharmaceuticals Inc. ORMP-2.3 million shares · -73%
- Atea Pharmaceuticals Inc. AVIR-106,327 shares · -2%
Sold out of 1
- Kezar Life Sciences Inc. KZR$5.3 million last quarter
What it holds
| Company | Shares | Value | Of its book | Change in shares |
|---|---|---|---|---|
| Aclaris Therapeutics Inc. ACRS | 12.0M | $63.3 million | 36.18% | -2.3M |
| Atea Pharmaceuticals Inc. AVIR | 7.0M | $32.3 million | 18.46% | -106.3K |
| Engene Therapeut ENGN | 6.7M | $11.5 million | 6.59% | new |
| Kraft Heinz Co. KHC | 465.0K | $11.0 million | 6.27% | +340.0K |
| Outset Med Inc. OM | 2.5M | $10.9 million | 6.22% | +617.5K |
| Carmax Inc. KMX | 172.5K | $9.1 million | 5.21% | +17.5K |
| Tillys Inc. TLYS | 2.1M | $9.0 million | 5.16% | no change |
| PMV Pharmaceuticals Inc. PMVP | 5.3M | $7.1 million | 4.08% | +10.0K |
| Instil Bio Inc. TIL | 645.6K | $5.0 million | 2.84% | no change |
| Target Corp. TGT | 37.5K | $4.9 million | 2.80% | no change |
| Oramed Pharmaceuticals Inc. ORMP | 866.3K | $4.2 million | 2.38% | -2.3M |
| Janux Therapeutics Inc. JANX | 155.0K | $2.4 million | 1.36% | no change |
| Pliant Therapeutics Inc. PLRX | 1.5M | $1.8 million | 1.01% | no change |
| Connect Biopharma Hldgs Ltd CNTB | 573.3K | $1.4 million | 0.78% | +164.4K |
| Imagenebio Inc. IMA | 200.7K | $1.2 million | 0.68% | no change |
Read more
Change is shares against its 13F for the quarter before; the 1 it sold out of are in the box above.Options it reported
| Company | Option | Shares under the options | Value of those shares |
|---|---|---|---|
| Walmart Inc. WMT | Puts | 335 | $386,088 |
| Core Scientific, Inc. CORZ | Puts | 800 | $298,000 |
| Tesla, Inc. TSLA | Puts | 375 | $270,000 |
3 option lines. A 13F lists calls and puts by the shares they cover and what those shares were worth at the quarter's end, not what the options cost; they are not counted in the holdings above.